Literature DB >> 19522981

Defining cancer risk in dermatomyositis. Part I.

V Madan1, H Chinoy, C E M Griffiths, R G Cooper.   

Abstract

The idiopathic inflammatory myopathies (IIMs) comprise polymyositis, myositis overlapping with another connective tissue disease, dermatomyositis (DM) and inclusion-body myositis (IBM). IIMs are characterized by the presence of proximal muscle weakness, increased levels of muscle-specific enzymes, specific electromyographic abnormalities, and the presence of inflammatory cell infiltrates in skeletal muscle. Clinical, serological and histological criteria can be used to define individual IIM subtypes. In the first of this two-part review series, we examine the evidence for the existence of cancer-associated myositis (CAM), and in part 2, we discuss recent discoveries that provide insight into identification of patients with DM, who may be most at risk of developing CAM.

Entities:  

Mesh:

Year:  2009        PMID: 19522981     DOI: 10.1111/j.1365-2230.2009.03216.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  12 in total

1.  Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; Frederick W Miller
Journal:  JAMA       Date:  2011-01-12       Impact factor: 56.272

2.  An atypical case of dermatomyositis associated with chromophobe renal cell carcinoma.

Authors:  Michael David George; Arash H Lahouti; Lisa Christopher-Stine
Journal:  BMJ Case Rep       Date:  2016-01-19

Review 3.  Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis.

Authors:  David F Fiorentino; Livia Casciola-Rosen
Journal:  Clin Rev Allergy Immunol       Date:  2022-05-20       Impact factor: 8.667

Review 4.  Idiopathic inflammatory myopathies.

Authors:  Ingrid E Lundberg; Manabu Fujimoto; Jiri Vencovsky; Rohit Aggarwal; Marie Holmqvist; Lisa Christopher-Stine; Andrew L Mammen; Frederick W Miller
Journal:  Nat Rev Dis Primers       Date:  2021-12-02       Impact factor: 52.329

5.  Multivalent Chromatin Engagement and Inter-domain Crosstalk Regulate MORC3 ATPase.

Authors:  Forest H Andrews; Qiong Tong; Kelly D Sullivan; Evan M Cornett; Yi Zhang; Muzaffar Ali; JaeWoo Ahn; Ahway Pandey; Angela H Guo; Brian D Strahl; James C Costello; Joaquin M Espinosa; Scott B Rothbart; Tatiana G Kutateladze
Journal:  Cell Rep       Date:  2016-09-20       Impact factor: 9.423

Review 6.  [Inflammatory myopathies].

Authors:  B Schoser
Journal:  Z Rheumatol       Date:  2009-10       Impact factor: 1.372

7.  Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

Authors:  David F Fiorentino; Lorinda S Chung; Lisa Christopher-Stine; Lisa Zaba; Shufeng Li; Andrew L Mammen; Antony Rosen; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2013-11

8.  Clinical features of inflammatory myopathies and their association with malignancy: a systematic review in asian population.

Authors:  Patompong Ungprasert; Napat Leeaphorn; Nattamol Hosiriluck; Wikrom Chaiwatcharayut; Nischala Ammannagari; Donald A Raddatz
Journal:  ISRN Rheumatol       Date:  2013-02-25

9.  Clinical presentation and evaluation of dermatomyositis.

Authors:  Umaima Marvi; Lorinda Chung; David F Fiorentino
Journal:  Indian J Dermatol       Date:  2012-09       Impact factor: 1.494

10.  Characteristics and predictors of malignancy in dermatomyositis: Analysis of 239 patients from northern China.

Authors:  Ying Liu; Lulu Xu; Hongliang Wu; Na Zhao; Yanchun Tang; Xiaoping Li; Ying Liang
Journal:  Oncol Lett       Date:  2018-09-05       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.